Tools help Riverside Healthcare ID patients for breast MRIs

The use of evidence-based risk assessment tools were able to identify and screen women who have an elevated risk for hereditary cancer and are eligible for breast MRI surveillance.

The assessment tools—from software vendor CancerIQ—more than doubled the patients eligible for ongoing MRI surveillance to detect cancer earlier, according to a study conducted at Riverside Healthcare in Kankakee, Illinois.

Riverside Healthcare includes 313-bed Riverside Medical Center and a physician medical group serving five Illinois counties and parts of western Indiana.

riverside-healthcare.jpg
Jensen & Halstead-Riverside Medical Center

Also See: Study finds radiologists easily transition to 3D mammography

About 2.7 million women nationwide are estimated to have an elevated hereditary risk for breast and ovarian cancer and most are not identified because of challenges among various screening processes, according to National Comprehensive Cancer Network guidelines.

“Cancer IQ’s technology helped us overcome barriers to identifying women at increased risk by simplifying the screening process, providing immediate determination of risk and reducing stress levels for both patients and our mammography technicians,” says Julie Sieling, creator of the screening program at Riverside Healthcare and lead author of the study.

The vendor’s software enables hospitals to analyze family history and run predictive risk models, as well as identify, evaluate and manage patient populations based on individuals’ genetic risk factors.

Sharp Healthcare also has partnered with Cancer IQ and has seen increased MRI screenings and a patient volume increase of 40 percent, while streamlining referrals and improving physician satisfaction via increased revenue.

“Results achieved by Riverside Healthcare and other partners continue to validate our approach to making genetic information more widely available to patients and providers so they can act sooner to mitigate risk,” adds Feyi Olopade Ayodele, CEO at CancerIQ.

For reprint and licensing requests for this article, click here.